Inogen (INGN) to Release Quarterly Earnings on Tuesday

Inogen (NASDAQ:INGN) is set to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Inogen to post earnings of ($0.76) per share for the quarter. Inogen has set its Q1 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.49). Inogen had a negative net margin of 32.46% and a negative return on equity of 38.98%. The company had revenue of $75.90 million for the quarter, compared to the consensus estimate of $78.09 million. On average, analysts expect Inogen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Inogen Trading Up 1.7 %

Shares of INGN stock opened at $7.15 on Monday. The stock has a market capitalization of $168.38 million, a P/E ratio of -1.62 and a beta of 1.10. The firm’s 50 day moving average is $7.16 and its 200 day moving average is $6.46. Inogen has a 12-month low of $4.13 and a 12-month high of $13.86.

Analyst Upgrades and Downgrades

Several research firms have issued reports on INGN. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Tuesday, April 9th. William Blair upgraded shares of Inogen from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.50.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.